41 results about "Virus Structural Proteins" patented technology

The invention discloses an immunological composition which comprises porcine Seneca virus structural protein VP3 and VP1 proteins, as well as porcine Seneca virus structural protein VP2 and/or VP4 protein. Further, the immunological composition can further comprise a porcine Seneca virus structural protein VP0. The immunological composition can be used for preparing a novel genetic engineering subunit vaccine of porcine Seneca virus, the antigenicity, immunogenicity and function of the vaccine are similar to those of natural proteins, the expression level is relatively high, the immunogenicity is strong, and no pathogenicity is caused to animals; the vaccine can be prepared by large-scale serum-free suspension culture in a bioreactor, thereby greatly reducing the cost of vaccine production.

The invention discloses a hepatitis E virus-like particle vaccine preparation method, and belongs to the biological medicine technical field. According to the method, hepatitis E virus truncated capsid protein gene codon optimization is performed, prokaryotic expression system escherichia coli strain B834-pRARE2 is used, by fusion of purification tag MBP expression, different cracking agent screening and combination, bacterial membrane extraction, maltose amylose affinity chromatography, molecular sieve chromatography for removal of MBP and non-virus structural protein, and promotion of virus-like particle assembly, the hepatitis E virus-like particle purity is more than 99.0%, and is free of protein label and bioactive (in the form of non-inclusion body, and soluble). The hepatitis E virus-like particle vaccine produces complete protection to pig, dog and chicken HEV infection, cross protective antigens are between different genotype HEV virus, and the hepatitis E virus-like particle vaccine can be used as an animal vaccine to prevent the diseases and infection caused by pig, dog and poultry HEV.

The present invention discloses a viral myocarditis gene vaccine, Said vaccine is constructed by using B3 type Coxsackie virus structural protein VPI gene and pcDNA carrier together, and its exterior is covered with a biological polysaccharide. It also discloses a method for preparing said gene vaccine and the application of said gene vaccine in preparation of medicine for preventing viral myocarditis.

The invention discloses a mud crab bicistronic mRNA virus structural protein 1, a monoclonal antibody thereof and the application. The amino acid sequence of the mud crab bicistronic mRNA virus structural protein 1 is SEQ ID NO: 3 and the nucleotide sequence is SEQ ID NO: 1. By researching and analyzing MCDV, the invention firstly obtains the amino acid sequence, the nucleotide sequence and the monoclonal antibody of the structural protein 1, locates the structural protein 1 and provides a new research direction for researching virus of mud crab bicistronic mRNA. The monoclonal antibody of the structural protein 1 can be used in monitoring MCDV, preparing a virus kit for detecting MCDV and preparing a virus colloidal gold test paper for detecting MCDV.

The invention discloses a replication-defective A virus expression vector system and a vaccine preparation method. The vector system consists of a replication-defective A virus vector of a deleted structural gene and minus strand complementary plasmids or cells containing a controllable virus A structural gene. In the preparation method, an exogenous gene target is introduced by constructing the replication-defective A virus vector of a deleted virus structural protein; and the replication-recombinant A virus can be continuously produced in a large scale by combining the minus strand complementary plasmids or cells containing the controllable A virus structural gene, so that the problem of low virus yield of a conventional A virus system can be solved, a target of preparing recombinant virus in a large scale is realized, and exogenous protein and virus sample particles can be expressed in scale. The replication-defective A virus expression vector system disclosed by the invention is suitable for large-scale production of DNA (deoxyribonucleic acid) vaccine, vector virus vaccine and exogenous protein expression.

The invention belongs to the technical field of biological medicines, and relates to cloning, construction and application of a new coronavirus SARS-CoV-2 subgenome replicon based on a bacterial artificial chromosome BAC. The invention provides an expression product cloned by a new coronavirus subgenome replicon, the expression product does not contain structural protein S, M or E of the new coronavirus, and the invention also comprises a coding sequence, a preparation method and application of the expression product. The invention relates to DNA (Deoxyribose Nucleic Acid) cloning of a new coronavirus (SARS-CoV-2) with a Gaussian luciferase reporter gene based on a bacterial artificial chromosome BAC (Bacterial Artificial Chromosome); four DNA clones respectively containing four new coronavirus gene segments and a reporter gene Gluc; the invention also discloses a preparation method of a new coronavirus (SARS-CoV-2) subgenome replicon by removing virus structural proteins S, M and E and adding a reporter gene. The system provided by the invention can be used for screening new coronavirus antiviral drugs.

The invention relates to the technical field of molecular biology, in particular to an A-type foot-and-mouth disease subunit vaccine as well as a preparation method and application thereof. Accordingto the invention, optimization design is performed based on amino acid sequences of three kinds of structural proteins VP0, VP3 and VP1 of an A-type foot-and-mouth disease virus epidemic strain (A/GDMM/2013) in 2013 in China, a single plasmid is screened out by means of small ubiquitin-related modifier (SUMO) fusion protein to simultaneously express the three kinds of structural proteins efficiently, uniformly and solubly in escherichia coli, and the three kinds of virus structural proteins are successfully self-assembled in vitro; and finally obtained target protein accounts for about 30% orabove of total bacterial protein, and the maximum yield of the purified target protein can reach 150 mg/L. The foot-and-mouth disease vaccine prepared with the method disclosed by the invention has agood protection effect on A-type foot-and-mouth disease epidemic viruses in China, and the minimum full-protection immune dose of the vaccine can be as low as 20 micrograms per vaccine.

On the basis of AI-Deep-Learning technical research, activation of an MHC-I immune system is taken as a target, research is carried out aiming at CoViD-19 virus structural protein, polypeptide sequences with the length of 9-14 amino acids are predicted, the polypeptides can obviously activate the immune system of a body, and a foundation is laid for designing a safe and effective polypeptide vaccine.

The invention discloses a trivalent recombinant adenovirus vaccine for foot-and-mouth disease and a construction method of the trivalent recombinant adenovirus vaccine. The trivalent recombinant adenovirus vaccine is obtained by constructing a recombinant adenovirus vector co-expressed by three antigen genes of a foot-and-mouth disease virus and packaging the recombinant adenovirus vector by AY293-6015 cells, and the trivalent recombinant adenovirus vaccine can be used for simultaneously preventing three serotype foot-and-mouth diseases. E1, E3 and E4 genes of an adenovirus vector are knocked out through CRISPR, and shuttle plasmids in E1 and E4 regions are constructed and are separately used for expressing A-P12A, OBY-P12A and OXJ-P12A-3C-mutant genes; and three foot-and-mouth disease virus structural proteins share one 3C protease to form a VLP, compared with a first-generation adenovirus vector, the vector capacity is increased by about 3kb, a recombinant adenovirus with high titer can be obtained, and the vaccine capacity can be greatly improved when the recombinant adenovirus vector is used for preparing a recombinant adenovirus vaccine for the foot-and-mouth disease. Due to a mode of simultaneously expressing independent-complete-structure protein antigens of three foot-and-mouth disease epidemic strains on one adenovirus vector, foot-and-mouth disease virus A type, O type BY strains and O type XJ strains can be simultaneously prevented, and the specific immune response to the foot-and-mouth disease virus can be enhanced.

The invention discloses a protein bonded with rabbit hemorrhagic disease virus (RHDV) VP60 protein and application thereof. The protein is characterized by comprising at least one sequence which is shown as SEQ ID NO: 1. In the invention, moesin (MSN) which interacts with rabbit hemorrhagic disease virus structural protein VP60 is tagged from a rabbit liver tissue complementary DNA (cDNA) librarythrough a yeast two-hybrid technology. Immunoprecipitation tests verify that the protein has the function of being bonded with virus particles in vitro; and the purified MSN protein can inhibit the agglutination effect of 8 hemagglutination units of virus antigen on human O-shaped erythrocytes. The protein and the rabbit hemorrhagic disease virus are incubated at room temperature; an anti-RHDV negative rabbit is inoculated through oral administration and nasal dripping, still survives after 8 days and is healthy-looking; and pathological anatomy and excisional biopsy show that each visceral organ is normal. The rabbit which is infected by the virus dies in 3 days. Thus, the protein can be used for preparation of medicaments for treating rabbit hemorrhagic disease.

The invention discloses a recombinant plasmid for expressing infectious bursal disease virus structural protein VP2; the recombinant plasmid mainly comprises infectious bursal disease virus structural protein VP2 gene, avian Ub gene and eukaryotic expression vector pVAX1. Therefore, the inventor designs and establishes a corresponding infectious bursal disease virus recombinant ubiquitinated DNA vaccine and a preparation method thereof. Compared with the prior art, the vaccine has the advantages of good manufacture simplicity, low cost, high safety, and good immunization effect. Tests indicate that the vaccine is effective in avoiding and decreasing damage and chicken mortality of immune organs, such as bursa of Fabricius, due to infectious bursal disease.

The invention relates to the technical field of biology, in particular to an O-type foot and mouth disease virus structural protein antibody, a preparation method and application. The O-type foot-and-mouth disease virus 146s is used as an immunogen to immunize a Balb/c mouse, a hybridoma cell line capable of efficiently secreting the monoclonal antibody is obtained through cell fusion, and the mouse monoclonal antibody m19 is obtained. Indirect immunofluorescence tests show that the monoclonal antibody m19 has good reactivity to O-type strains of different lineages and does not react with A-type strains of different lineages. The O-type foot-and-mouth disease virus structural protein solid-phase competitive ELISA detection kit is established by utilizing the monoclonal antibody m19 and O-type structural protein rabbit antiserum, compared with an existing antibody, the sensitivity and specificity of a detection result are remarkably improved, the kit is suitable for detection of structural protein antibodies after O-type foot-and-mouth disease infection or inactivated vaccine immunization, and meanwhile, the kit can be used for detecting the structural protein antibodies after O-type foot-and-mouth disease infection or inactivated vaccine immunization. And the method is a novel method for monitoring the infection condition of the non-immune area of the foot-and-mouth disease.